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Abstract 22 
This study investigates the ability of milk protein-derived peptides to specifically activate the 23 
serotonin 2C (5-HT2C) receptor, a key receptor in central regulation of food intake. A dose 24 
dependent 5-HT2C receptor activation by the 1 kDa ultrafiltration permeates of a sodium 25 
caseinate (NaCNH-1 kDa permeate) and a whey protein hydrolysate (WPH-1 kDa permeate) 26 
was demonstrated using an intracellular calcium mobilization assay in human embryonic 27 
kidney (Hek) cells expressing the 5-HT2C receptor. Both samples activated the 5-HT2C but not 28 
the 5-HT2A and 5-HT2B receptors. NaCNH-1 kDa permeate significantly (p < 0.01) reduced 29 
cumulative food intake when administered to male mice (C57Bl/6) by intraperitoneal 30 
injection at 500 mg kg
-1 
body weight. In contrast, no effect of WPH-1 kDa permeate could be 31 
seen on food intake in vivo. These results demonstrate the promising appetite-suppressing 32 
potential of NaCN-derived peptides, targeting the 5-HT2C receptor.   33 
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1. Introduction 34 
As the incidence of obesity and its co-morbidities are increasing worldwide, so too does the 35 
need for novel anti-obesity intervention strategies (Bloom et al., 2008; Nguyen et al., 2012). 36 
Current anti-obesity treatments consist of dietary and lifestyle interventions as well as 37 
pharmaceutical drug treatments and surgery (Aronne, Powell, & Apovian, 2011; Cecchini et 38 
al., 2010; Derosa & Maffioli, 2012; Halford, Boyland, Blundell, Kirkham, & Harrold, 2010; 39 
Kang & Park, 2012; Powell, Apovian, & Aronne, 2011; Powell & Khera, 2010; Schellekens, 40 
Dinan, & Cryan, 2009). However, most pharmaceutical drug candidates have so far failed to 41 
reach the market, due to their low potency and efficacy or side effects and safety concerns 42 
(Aronne et al., 2011; Chakrabarti, 2009; Derosa & Maffioli, 2012; Kang & Park, 2012; 43 
Kennett & Clifton, 2010). Moreover, diets are generally associated with a low success rate 44 
due to poor adherence and compliance. Bioactive peptides from natural sources may have 45 
potential as weight management ingredients and are becoming of considerable interest in the 46 
food industry to counteract obesity when incorporated into the diet (Gonzalez-Castejon & 47 
Rodriguez-Casado, 2011; Gooda Sahib et al., 2012).
 
48 
 
49 
Weight loss can be achieved following the modulation of appetite and satiety signalling 50 
pathways in the central nervous system (CNS) (Obici, 2009; Valentino, Lin, & Waldman, 51 
2010). Modulation of the central serotonergic system, in particular activation of the centrally 52 
expressed serotonin (5-hydroxytryptamine, 5-HT) 2C receptor (5-HT2C), stimulates satiety 53 
via excitatory neurotransmission. Therefore, activation of the 5-HT2C receptor is a target for 54 
anti-obesity strategies (Dutton & Barnes, 2006; Garfield & Heisler, 2009; Lam et al., 2008; 55 
Miller, 2005b; Schellekens, Clarke, Jeffery, Dinan, & Cryan, 2012a; Somerville, Horwood, 56 
Lee, Kennett, & Clifton, 2007; Tecott et al., 1995; Tecott, 2007; Vickers, Clifton, Dourish, & 57 
Tecott, 1999). Several drugs targeting the central serotonergic system, such as sibutramine, 58 
DOI: 10.1016/j.idairyj.2014.04.004 
4 
 
and fenfluramine, have been specifically developed to induce satiety, or as for m-59 
chlorophenylpiperazine (mCPP), found to reduce food intake as a secondary effect (Dalton, 60 
Lee, Kennett, Dourish, & Clifton, 2004, 2006; Halford, Harrold, Boyland, Lawton, & 61 
Blundell, 2007; Vickers et al., 1999). However, these drugs have been associated with poor 62 
efficacy and safety concerns due to heart and pulmonary vasculature side-effects and non-63 
specific effects (Miller, 2005b). Recently, the specific 5-HT2C receptor agonist, Lorcaserin, 64 
was approved for the treatment of obesity (Jandacek, 2005; Martin et al., 2011; O'Neil et al., 65 
2012; Redman & Ravussin, 2010). This highlights the benefits of targeting the 5-HT2C 66 
receptor in weight management strategies. Natural compounds, including milk protein-67 
derived bioactive peptides, are presumed to be safe because they are derived from food 68 
sources. In addition, they have not been associated with the undesirable side effects, which 69 
are often encountered with pharmaceutical drugs. 70 
Milk proteins represent a unique source of biologically active peptides which have been 71 
associated with various health benefits (FitzGerald, Murray, & Walsh, 2004; Korhonen, 72 
2009; Kreider et al., 2011; Lonnerdal, 2003; Meisel & FitzGerald, 2003; Nagpal et al., 2011; 73 
Phelan & Kerins, 2011). These include anti-hypertensive, mineral binding, antimicrobial, 74 
immuno-regulatory, antidiabetic, antioxidant and opioid peptides (Booij, Merens, Markus, & 75 
Van der Does, 2006; Froetschel, Azain, Edwards, Barb, & Amos, 2001; Korhonen, Marnila, 76 
& Gill, 2000; Kumar et al., 2012; Nongonierma & FitzGerald, 2012b; Nongonierma & 77 
FitzGerald, 2013; Orosco et al., 2004; Power, Jakeman, & FitzGerald, 2013; Virtanen, 78 
Pihlanto, Akkanen, & Korhonen, 2007). In particular, the satiating effects of milk proteins 79 
and milk protein-derived peptides may play a role in appetite regulation, weight loss and/or 80 
prevention of weight gain (Anderson, Tecimer, Shah, & Zafar, 2004; Burton-Freeman, 2008; 81 
Dougkas, Reynolds, Givens, Elwood, & Minihane, 2011; Luhovyy, Akhavan, & Anderson, 82 
2007; Pilvi, Korpela, Huttunen, Vapaatalo, & Mervaala, 2007; Pilvi et al., 2008; Ricci-83 
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Cabello, Herrera, & Artacho, 2012; Staljanssens et al., 2011; van Meijl, Vrolix, & Mensink, 84 
2008; Veldhorst et al., 2009; Zemel, 2005).  85 
It has been demonstrated that diets rich in -lactalbumin could enhance 5-HT release in rats 86 
(Orosco et al., 2004) and in humans (Booij et al., 2006; Nieuwenhuizen et al., 2009). This 87 
was attributed to a higher bioavailability of tryptophan, the precursor of 5-HT. In addition, 88 
the milk protein-derived bioactive peptide, β-casomorphin-7 (Tyr-Pro-Phe-Val-Glu-Pro-Ile), 89 
has been shown to bind and antagonize 5-HT2 receptors (Sokolov et al., 2005). 90 
Recently, it was demonstrated that milk protein hydrolysates generated from different starting 91 
substrates, including sodium caseinate (NaCN), acid casein, skim milk powder and 92 
glycomacropeptide, behave as 5-HT2C receptor agonists in vitro (Nongonierma, Schellekens, 93 
Dinan, Cryan, & FitzGerald, 2013). The aim of this study was to assess the role of NaCN-94 
derived and whey protein (WP)-derived bioactive peptides on 5-HT2C receptor agonism. In 95 
addition, the specificity of NaCN and WP-derived bioactive peptides for the 5-HT2C receptor 96 
over the closely related 5-HT2A and 5-HT2B receptors was studied. Finally, the effect of 97 
NaCN and WP hydrolysates on cumulative food intake in mice was assessed as a measure of 98 
the satiety inducing potential of these milk protein-derived peptides in vivo. Milk protein-99 
derived bioactive peptides with 5-HT2C receptor agonist properties may have considerable 100 
potential in the development of non-pharmacological weight management ingredients and 101 
may be exploited in the development of anti-obesity functional foods.    102 
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2. Materials and methods 103 
2.1. Generation of the milk protein hydrolysates and their associated ultrafiltration fractions 104 
The experimental design of this study is summarized in Fig. 1. Sodium caseinate (NaCN, 105 
90.4% (w/w) protein) was provided by Kerry Ingredients (Listowel, Co. Kerry, Ireland) and 106 
whey proteins (WP, 88.3% (w/w) protein) were from Carbery Milk Products (Ballineen, Co. 107 
Cork, Ireland). The 240 min NaCN hydrolysate (NaCNH) was produced by enzymatic 108 
hydrolysis as per Nongonierma et al. (2013). The whey protein hydrolysates (WPH) were 109 
generated using similar enzymatic hydrolysis conditions as for the NaCNH. Briefly, an 110 
aqueous solution of WP (10 % (w/v) on a protein basis) was rehydrated for 1 h at 50°C with 111 
gentle mixing. The pH was adjusted to 3.0 with 1.0 N HCl before addition of pepsin. The pH 112 
of the reaction mixture was maintained constant throughout hydrolysis using a pH stat titrator 113 
(Titrando 843, Tiamo 1.4 Metrohm, Dublin, Ireland) for 4 h. In addition, aliquots of the WPH 114 
were withdrawn at 10, 30, 60, 120 min throughout the hydrolysis reaction. WPH was 115 
generated in two independent duplicates (n=2). The enzyme was heat inactivated at 90°C for 116 
20 min. The 4h WPH was further fractionated by ultrafiltration (UF) using a cross-flow 117 
ultrafiltration unit (Sartoflow Alpha filtration System, Sartorius, Göttingen, Germany). WPH 118 
was sequentially UF fractionated through a 10, 5 and then a 1 kDa molecular weight cut-off 119 
(MWCO) stabilized cellulose UF cassette (Sartorius). Ultrafiltration was carried out at 30°C. 120 
Six fractions of WPH were collected (10, 5 and 1 kDa permeate and retentate). The samples 121 
were freeze-dried (FreeZone 18L, Labconco, Kansas City, U.S.A.) and stored at -20C until 122 
utilization. 123 
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2.2. Reverse phase-ultraperformance liquid chromatography (RP-UPLC) and gel permeation 124 
-high performance liquid chromatography (GP-HPLC) analysis of WPH and its associated 125 
UF fractions 126 
Unhydrolysed whey proteins (WP), WPH and its UF fractions were analysed with an Acquity 127 
UPLC (Waters, Dublin, Ireland) as described by Nongonierma and FitzGerald (2012a). 128 
Samples were resuspended at 0.5 % (w/v) in 0.1 % (v/v) trifluoro acetic acid (TFA, Sigma-129 
Aldrich, Dublin, Ireland) in HPLC grade water (VWR, Dublin, Ireland). Separation of 130 
peptides and individual milk proteins was carried out at 30C using a 2.1 x 50 mm, 1.7 µm 131 
Acquity UPLC C18 BEH column mounted with a 0.2 µm inline filter (Waters). The 132 
absorbance of the eluant was monitored at 214 nm. 133 
The molecular mass profiles of the proteins and peptides present in the samples was 134 
determined by GP-HPLC as described by Spellman, O’Cuinn, and FitzGerald (2009). 135 
Samples were resuspended at 0.25 % (w/v) in 0.1% TFA and 30 % HPLC grade acetonitrile 136 
(ACN, WVR) in HPLC grade water. A 600 x 7.5 mm I.D. TSK G2000 SW column mounted 137 
with a 75 x 7.5 mm I.D. TSKGEL SW guard column (Tosoh Bioscience, Stuttgart, Germany) 138 
was used for the separation. The absorbance was monitored at 214 nm. 139 
2.3. Cell culture, in vitro transfection and lentiviral transduction 140 
Human embryonic kidney cells (Hek293A) were cultured and maintained in high glucose 141 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 10 % 142 
(v/v) heat inactivated foetal bovine serum (FBS, Sigma-Aldrich) and 1 % (v/v) Gibco® 143 
MEM non-essential amino acids  (NEAA, Life technologies, Biosciences, Dublin) in an 144 
atmosphere of 95 % air and 5 % CO2 at 37°C. Stably transfected Hek293A cells were 145 
maintained in complete media supplemented with 300 ng μL-1 geneticin (G418, Merck, 146 
Darmstadt, Germany) as maintenance antibiotic. Hek293A cells stably expressing the 147 
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unedited 5-HT2C-INI or the partly edited 5-HT2C-VSV isoform of the 5-HT2C receptor were 148 
generated as per Schellekens et al. (Schellekens, Dinan, & Cryan, 2013). Briefly, Hek293A 149 
cells were transfected with plasmid construct expressing the unedited INI (H3309; Accession 150 
code, NM_000868, Genecopeia, MD, U.S.A.) or the partly edited VSV isoform of the 5-HT2C 151 
receptor (Genecopeia, T0336, Accession code: AF208053.1) with a C-terminal-EGFP tag, 152 
from a CMV promoter using lipofectamine® LTX plus reagent from Invitrogen™ (Life 153 
technologies, Biosciences, Dublin ), according to the manufacturer's instructions. The 5-HT2A 154 
receptor was amplified from the commercial construct 3xHA-tagged (N-terminus) 5-HT2A 155 
(HTR02ATN00, Missouri S&T cDNA Resource Center; MO,  U.S.A.) and cloned into the 156 
pEGFP-N1 expression vector (6085-1, Clontech, Saint-Germain-en-Laye, France). Cells 157 
stably expressing the insert gene-EGFP fusion proteins were selected using flow assisted cell 158 
sorting (FACS, Becton Dickinson (BD) FACSVantage SE, Oxford, UK) and G418 as a 159 
selection antibiotic. Hek293A cells expressing the 5-HT2B receptor were generated using 160 
lentiviral transductions, using a third generation packaging, gene delivery and viral vector 161 
production system developed by Naldini and colleagues (Follenzi & Naldini, 2002a, 2002b; 162 
Naldini et al., 1996; Naldini, 1998; Vigna & Naldini, 2000). The 5-HT2B receptor (Missouri 163 
S&T; HTR02BTN00) construct was cloned into the lentiviral expression vector, pHR-SIN-164 
BX-EGFP, modified from the lentiviral expression plasmid pHR-SIN-BX-IRES-EmGFP 165 
vector (gift of Adrian Thrasher, Institute of Child Health, London, United Kingdom). The 166 
generated HIV-based lentiviral vector (lv) particles, pseudotyped with the vesicular stomatitis 167 
virus G (VSV-G), expressing the G-protein coupled receptor (GPCR) constructs from a 168 
spleen focus-forming virus (SFFV) promoter were produced using 293T-17 cells, following 169 
transient cotransfection of the cloned expression construct, pHR-5-HT2B-EGFP, the 170 
packaging construct, pCMVR8.91 and the envelope construct, pMD.G–VSVG. Cells were 171 
transduced with lv expressing the lv5-HT2B-EGFP receptor diluted in transduction media, 172 
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consisting of DMEM with 2 % (v/v) heat-inactivated FBS, 1 % (v/v) NEAA and an 173 
additional 8 μg mL-1 polybrene® (H9268, Sigma-Aldrich). Fluorescence was monitored 174 
using flow cytometry (BD FACS Calibur, BD Biosciences) as an indicator of receptor 175 
expression. 176 
2.4. Calcium (Ca
2+
) mobilization assay 177 
Receptor mediated changes in intracellular Ca
2+
 were monitored on a Flex station II 178 
multiplate fluorometer (Molecular Devices Corporation, Sunnyvale, CA, U.S.A.). Stably 179 
transfected cells were seeded in sterile black-wall and clear flat bottom 96-well microtiter 180 
plates (3904, Costar, Fisher Scientific, Dublin, Ireland) at a density of 2.5 x 10
5
 cells mL
-1 
181 
(i.e., 2.5 x 10
4 
cells/well) and maintained for ~ 24 h at 37°C in a humidified atmosphere 182 
containing 5 % CO2. After removal of the growth medium, cells were incubated with 25 µL 183 
of assay buffer (1x Hank’s buffered salt solution (HBSS) supplemented with 20 mM HEPES 184 
buffer) and 25 µl of Ca
2+
 4 dye (R8141, Molecular Devices Corporation) according to the 185 
manufacturer’s protocol. FBS (Sigma-Aldrich) and 5-HT (H9523; Sigma-Aldrich) diluted in 186 
assay buffer were used as controls. Milk protein hydrolysates were resuspended in assay 187 
buffer (1x HBSS supplemented with 20 mM HEPES buffer). Suspensions were centrifuged at 188 
2000 rpm (Jouan C3i multifunction centrifuge, Thermo Scientific, Dublin, Ireland) for 5 min 189 
at 4°C and filtered through 0.45 µm low protein binding filters (Sartorius, Dublin, Ireland). 190 
Hydrolysates were tested at the concentration of 1 mg mL
l 
in duplicate or triplicate. Test and 191 
control samples (25 µL/well) were directly added to cells using a Flexstation II and 192 
fluorescent readings were taken for 80 s in flex mode with excitation and emission 193 
wavelengths of 485 and 525 nm, respectively. The change in intracellular Ca
2+
 was 194 
monitored as an increase in relative fluorescence units (RFU), and the difference between 195 
maximum and minimum RFU (Vmax-Vmin) was compared and depicted as percentage of  196 
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maximum Ca
2+
 influx as elicited by the controls (5-HT or FBS, as indicated). For dose 197 
response curves, data analysis was performed using PRISM 4.0 (GraphPAD Software Inc., 198 
CA, U.S.A.). 199 
2.5. Reverse-phase high performance liquid chromatography (RP-HPLC) to quantify L-200 
tryptophan and serotonin  201 
For quantification of L-tryptophan, the HPLC system consisted of a 510 pump, a 717 plus 202 
autosampler cooled at 4°C, a 486 absorbance detector, a bus SAT/IN module (Waters, 203 
Dublin), a croco-cil column oven and a 1046A Fluorescent Detector (Hewlett Packard, 204 
supplied by Agilent Technologies, Dublin). All samples were injected onto a RP Luna 3 μm 205 
C18 150 × 2 mm column (Phenomenex, London, UK), mounted with a Krudkatcher pre-206 
column filter and security guard cartridges (Phenomenex). The analytical method was 207 
adapted from Herve, Beyne, Jamault, and Delacoux (1996). The mobile phase consisted of 50 208 
mM acetic acid (Alkem/Reagecon, Cork, Ireland), 100 mM zinc acetate (Alkem/Reagecon) 209 
with 3 % (v/v) acetonitrile (Alkem/Reagecon) and was filtered through a 0.45 μm Millipore 210 
Durapore filter (AGB, Dublin) and vacuum degassed prior to use. Separations were achieved 211 
by isocratic elution at 0.3 mL min
-1
. The fluorescent detector was set to excitation and 212 
emission wavelengths of 254 and 404 nm, respectively. The UV detector was set at 330 nm. 213 
Samples were deproteinized by the addition of 20 μL of 4 M perchloric acid 214 
(Alkem/Reagecon) to 200 μL of sample spiked with 3-nitro-L-tyrosine (Sigma-Aldrich) as 215 
internal standard. A 20 μL aliquot of sample or standard (L-tryptophan, Sigma-Aldrich) was 216 
injected onto the HPLC column and results were processed using Empower® software 217 
(Waters). Analytes were identified based on their retention time and concentrations were 218 
determined using analyte:internal standard peak height ratios which were compared with 219 
standard injections. Results were expressed as ng L-tryptophan mg
-1
 of sample. 220 
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Serotonin concentration was determined using a different RP-HPLC system according to a 221 
modification of a previously described procedure (O'Mahony et al., 2008). The HPLC system 222 
consisted of a SCL 10-Avp system controller, LC-10AS pump, SIL-10A autoinjector (with 223 
sample cooler maintained at 4

C), CTO-10A oven, LECD 6A electrochemical detector 224 
(Shimadzu, Kyoto, Japan) and an online Gastorr degasser (ISS, Kent, UK). A RP column 225 
Kinetex 2.6 μm C18 100 × 4.6 mm (Phenomenex) maintained at 30C was employed for 226 
analyte separation at a flow rate 0.9 mL.min
-1
. The glassy carbon working electrode 227 
combined with an Ag/AgCl reference electrode (Shimadzu) was operated a + 0.8 V and the 228 
results were analysed using Class-VP 5 software (Shimadzu). The mobile phase, which 229 
contained 0.1 M citric acid, 0.1 M sodium dihydrogen phosphate, 0.01 mM EDTA 230 
(Alkem/Reagecon), 5.6 mM octan-1-sulphonic acid (Sigma-Aldrich) and 9 % (v/v) methanol 231 
(Alkem/Reagecon), was adjusted to pH 2.8 using 4 N sodium hydroxide (Alkem/Reagecon). 232 
Briefly, samples were diluted either 1/3 or 1/10 in chilled (4°C) mobile phase spiked with 0.1 233 
ng μL-1 of N-methyl 5-HT (Sigma-Aldrich) as internal standard. Diluted samples were then 234 
centrifuged at 14,000 rpm (Hettich MIKRO 22 R, DJB Labcare, UK) for 15 min at 4C and 235 
20 μL of the supernatant was injected onto the HPLC column. Serotonin was identified by its 236 
retention time as determined from injection of serotonin standards. Serotonin concentrations 237 
were determined using the analyte:internal standard (N-methyl 5-HT) peak height ratios, 238 
which were compared with that of serotonin standard injections. Results were expressed as 239 
nM serotonin mg
-1
 of sample 240 
2.6. Cumulative food intake experiment. 241 
Animals, male C57Bl/6 mice were purchased from Harlan (Blackthorn, UK). Mice of 7 to 8 242 
week-old were received at the facility. Animals were group-housed (4 to 5 mice per cage) in 243 
standard holding cages with controlled light-dark cycle (12-h light; lights on at 7:45 a.m.) and 244 
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in a temperature- (21 ± 1°C) and humidity-controlled (55 ± 10 %) environment. Water and 245 
standard lab chow (2018S Teklad Global 18 % Protein Rodent Diet, Harlan, UK) were 246 
available ad libitum. All mice were weighed (precision 0.1 g) twice weekly and on the day of 247 
the study between 9:00 and 10:00 a.m. All experiments were in full accordance with the 248 
European Community Council directive (86/609/EEC) and approved by the Animal 249 
Experimentation Ethics Committee of University College Cork. Cumulative food intake was 250 
analysed during the light cycle following a 16 h fast during the dark phase as described 251 
previously (Vickers, Dourish, & Kennett, 2001). The fasting period prior to the study is 252 
warranted to induce a robust baseline feeding response, enabling studies with fewer animals. 253 
On the day of the study, mice were placed into individual housing cages and left to 254 
acclimatize for > 15 min. Animals were randomized into two groups (n = 10) and received an 255 
intraperitoneal (IP) injection with either vehicle (HBSS and 20 mM HEPES) or milk protein 256 
hydrolysate (WPH-1 kDa permeate or NaCNH-1 kDa permeate) resuspended in HBSS and 257 
20 mM HEPES. The milk protein hydrolysates were administered at 200 or 500 mg kg
-1
 body 258 
weight and animals were returned to their individual holding cages. A pre-weighed amount 259 
(5.00 ± 0.01 g) of standard lab chow was placed in the cages 20 min after IP injection of the 260 
sample or vehicle. Food intake was determined at regular intervals by measuring the 261 
cumulative amount of food consumed. 262 
2.7. Statistical analysis 263 
Statistical analyses were performed using SPSS software (IBM SPSS statistics 20, Chicago, 264 
IL, U.S.A.). A mean multi comparison for the Ca
2+
 mobilization assay was performed using 265 
one way ANOVA followed by Bonferroni post-hoc tests at a significance level of p < 0.05. 266 
Food intake measurements between groups were analysed using a one way, repeated 267 
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measures ANOVA followed by estimation of the parameters. If the data was non-spherical a 268 
Huynh-Feldt correction was applied. Graphs were expressed as mean ± SEM.  269 
3. Results and Discussion 270 
3.1. Serotonergic activity of WPH and its associated UF fractions 271 
In this study, WP-derived enzymatic hydrolysates were exposed to Hek cells expressing two 272 
isoforms of the 5-HT2C receptor, the unedited 5-HT2C-INI receptor or the partially edited 5-273 
HT2C-VSV receptor isoform. The partly edited 5-HT2C–VSV results from the distinctive 274 
ability of the 5-HT2C receptor to be modified by post-transcriptional RNA editing on 5 275 
specific nucleotide positions, converting an adenosine to inosine residues, causing amino acid 276 
sequence changes (Burns et al., 1997). It is the most abundantly expressed 5-HT2C receptor 277 
isoform in human brain regions, in particularly in the hypothalamus (Niswender, Copeland, 278 
Herrick-Davis, Emeson, & Sanders-Bush, 1999; Werry, Loiacono, Sexton, & Christopoulos, 279 
2008). In addition, increased editing of the 5-HT2C receptor has been associated with an 280 
altered feeding behaviour and fat mass, supporting the role for the 5-HT2C receptor in obesity 281 
(Kawahara et al., 2008; Olaghere da Silva et al.; Schellekens, Clarke, Jeffery, Dinan, & 282 
Cryan, 2012b). An in-house established medium throughput cellular based screening platform 283 
was utilized to screen whey protein-derived hydrolysates for their 5-HT2C receptor activating 284 
potential. 285 
The WPHs sampled at different hydrolysis times were able to significantly induce 286 
intracellular Ca
2+
 mobilization in Hek cells stably expressing both isoforms of the 5-HT2C 287 
receptor compared to wild type cells, albeit lower in cells expressing the partially edited 5-288 
HT2C–VSV isoform (Fig. 2A). This was expected, as increased 5-HT2C receptor editing has 289 
been associated with a decreased receptor signalling (Berg, Clarke, Cunningham, & 290 
Spampinato, 2008; Burns et al., 1997; Niswender et al., 1999; Olaghere da Silva et al., 2010; 291 
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Schellekens et al., 2012a). Interestingly, unhydrolysed WP was also able to increase 292 
intracellular Ca
2+
 to some extent in cells expressing the 5-HT2C receptor isoforms. The 293 
relative Ca
2+
 influx in Hek cells expressing the 5-HT2C–INI isoform was similar at the 294 
different hydrolysis times studied. However, with the 5-HT2C–VSV isoform, an increase in 295 
relative Ca
2+
 influx was observed with increased hydrolysis time. In a previous study it was 296 
also demonstrated that with NaCNH, the 5-HT2C receptor mediated Ca
2+
 influx was 297 
significantly (p < 0.05) enhanced with increasing hydrolysis time (Nongonierma et al., 2013). 298 
Indeed, NaCNH was shown to induce a Ca
2+
 influx > 60 % of 5-HT2C receptor mediated Ca
2+
 299 
signalling compared to control. In contrast, here we demonstrate that WPHs herein were only 300 
able to mediate 50 % of 5-HT2C receptor mediated Ca
2+
 signalling compared to the control 301 
(Fig. 2A). Nevertheless, the independent duplicate of WPH gave similar activation of the 302 
serotonin 5-HT2C receptor (Table 1 and Fig. 2A), suggesting that the generation of the 303 
bioactive peptides was reproducible. 304 
Next, UF fractionation of the WPH 240 min hydrolysate was carried out. The RP-UPLC 305 
profiles of WP, WPH and its associated UF fractions are illustrated in Fig. 3. The WPH (Fig. 306 
3B) still contained unhydrolysed whey proteins (Fig. 3A), notably a high proportion of β-307 
lactoglobulin was still present within the hydrolysate. This is in agreement with the relatively 308 
high resistance of β-lactoglobulin to peptic hydrolysis (Reddy, Kella, & Kinsella, 1988). In 309 
agreement with the MWCO of the membranes, the unhydrolysed proteins were retained in the 310 
10 kDa retentate (Fig. 3C) and the 10, 5 and 1 kDa permeates did not contain any 311 
unhydrolysed WPs (Fig. 3D, 3E and 3F). The relative 5-HT2C receptor-mediated increase in 312 
intracellular Ca
2+
 was significantly higher in the 1, 5 and 10 kDa permeates compared to their 313 
associated retentates (Table 1). A one-way Anova comparisons revealed an overall significant 314 
increase in 5-HT2C receptor activation with UF fractionation (Table 1) of F(7) = 270.120; p < 315 
0.001. The molecular mass distribution profile of WPH and its associated UF fractions is 316 
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illustrated in Fig. 4. An enrichment in low molecular mass peptides was seen during 317 
sequential UF fractionation, with the 1 kDa permeate containing ~ 92% peptides < 1 kDa. 318 
The 5-HT2C receptor-mediated calcium increases were significantly higher in UF fractions 319 
enriched with low molecular mass peptides compared to unhydrolysed WP and WPH 240 320 
min (p < 0.001) (Table 1). This indicates that the low molecular mass peptides within the UF 321 
permeates were responsible for activation of the serotonin 5-HT2C receptor. Similar results 322 
were previously found with the NaCNH, also showing an increase in the 5-HT2C receptor 323 
activation with peptides having a molecular mass < 1 kDa (Nongonierma et al., 2013). 324 
Comparison of concentration response curves for NaCNH-1 kDa and WPH-1 kDa permeates 325 
demonstrated a similar efficacy (75-100 %) (Fig. 2B). However, the WPH-1 kDa permeate 326 
had a significantly higher (P < 0.05) potency when compared to NaCNH-1 kDa permeate 327 
(Fig. 2B), with absolute half maximal effective concentration (EC50) values of 0.022 and 328 
0.111 mg mL
-1
, respectively. 329 
 330 
3.2. Specificity of the NaCNH and WPH 1 kDa permeate samples across the serotonin 2 331 
receptor family 332 
As already outlined, the 5-HT2 receptor family constitutes three different receptor types, the 333 
5-HT2A, 5-HT2B and the 5-HT2C receptors (Hoyer et al., 1994; Hoyer, Hannon, & Martin, 334 
2002). Activation of these receptors has been implicated in several physiological functions of 335 
the CNS and in pathologies including anxiety, depression, migraine, satiety and 336 
schizophrenia (Baxter, Kennett, Blaney, & Blackburn, 1995). Previous studies have identified 337 
that activation of the 5-HT2B receptor by serotonergic drugs, including Fenfluramine, plays an 338 
important role in the occurrence of negative side-effects, including pulmonary hypertension, 339 
impaired regulation of plasma serotonin level and valvulopathy (Miller, 2005b; Rothman et 340 
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al., 2000). The first specific 5-HT2C receptor agonist, Lorcaserin, was recently approved for 341 
the treatment of obesity (Jandacek, 2005; Martin et al., 2011; O'Neil et al., 2012; Redman & 342 
Ravussin, 2010), reinforcing the importance of the 5-HT2C receptor as a target for weight 343 
management. Nevertheless, serotonergic drugs, including Lorcaserin, are associated with 344 
safety concerns due to non-specificity, in particular caused by the non-selective activation of 345 
the 5-HT2A and 5-HT2B receptors at the therapeutic dose. This has been suggested to be 346 
causal to heart and pulmonary vasculature side-effects (Miller, 2005a). The development of 347 
natural satiety inducing bioactives, such as milk protein–derived bioactive peptides 348 
specifically targeting the 5-HT2C receptor, may help to avoid the side-effects generally 349 
associated with the utilisation of pharmaceutical drugs. We therefore set out to investigate the 350 
5-HT2C receptor specificity for the most active compounds, i.e., the NaCNH-1 kDa and 351 
WPH-1 kDa permeates (Fig. 5). Both 1 kDa permeates induced significant Ca
2+
 mobilization 352 
in cells expressing the 5-HT2C receptor but not in cells expressing either the 5-HT2A or 5-353 
HT2B receptor, while 5-HT was shown to equally activate the three 5-HT2 receptors when 354 
tested at 1 mg mL
-1
 (Fig. 5). This shows that the milk-derived 1-kDa permeates are more 355 
specific for the 5-HT2C receptor compared to the 5-HT2A and 5-HT2B receptor, which 356 
indicates an advantageous safety profile. 357 
3.3. Serotonin and L-tryptophan concentrations in the NaCNH and WPH 1 kDa permeates 358 
It is well known that 5-HT and the 5-HT precursor L-tryptophan have appetite-suppressing 359 
activities. Therefore, 5-HT and free L-tryptophan concentrations within WP, WPH 240 min 360 
and the WPH-1 kDa permeate were determined. In addition, 5-HT and free L-tryptophan 361 
concentrations were determined in NaCN, NaCNH 240 min and the NaCNH 1 kDa permeate. 362 
None of the samples contained 5-HT. Moreover, unhydrolysed WP and NaCN were also void 363 
of free L-tryptophan. The NaCNH 240 min and WPH 240 min samples contained very low 364 
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concentrations of free L-tryptophan, i.e. 6 and 11 ng mg
-1
, respectively. The WPH and 365 
NaCNH-1 kDa permeates contained high to moderate concentrations of L-tryptophan, i.e., 366 
114 and 25 ng mg
-1
, respectively. Although L-tryptophan cannot directly bind the 5-HT2C 367 
receptor, it may contribute to potential satiety effects overall in vivo. However, this cannot 368 
explain the potent direct activation of the 5-HT2C receptor in vitro by the WPH-1 kDa 369 
permeate. This suggests that milk protein-derived peptides within NaCNH-1 kDa permeate 370 
were responsible for activation of the 5-HT2C receptor. 371 
3.4. Effect of NaCNH and WPH 1 kDa permeates on cumulative food intake in mice 372 
Milk protein-derived bioactives have been shown to stimulate the release of various gut 373 
hormones associated with the regulation of food intake, including cholecystokinin (CCK) 374 
(Bowen, Noakes, Trenerry, & Clifton, 2006b; Figlewicz et al., 1992; Hall, Millward, Long, & 375 
Morgan, 2003), peptide YY (PYY) (Calbet & Holst, 2004; le Roux & Bloom, 2005), 376 
glucagon-like peptide 1 (GLP-1) (Aziz & Anderson, 2003; Hall et al., 2003) and ghrelin 377 
(Bowen, Noakes, & Clifton, 2006a; Bowen et al., 2006b; Williams & Cummings, 2005). 378 
Lactoferrin has recently been reported to reduce abdominal obesity via modulation of 379 
lipopolysaccharide levels and composition (Ono, Morishita, & Murakoshi, 2013). In humans, 380 
chronic intake of lactoferrin has also been associated with a decrease in visceral fat (Ono et 381 
al., 2010). Similarly, intake of α-lactalbumin has been reported to reduce hunger, increase 382 
energy expenditure, and to regulate protein and fat balance (Hursel, van der Zee, & 383 
Westerterp-Plantenga, 2010). The satiety effects of α-lactalbumin have been linked with the 384 
higher bioavailability of tryptophan, the 5-HT precursor. Thus, ingestion of α-lactalbumin 385 
increases 5-HT release in rats (Orosco et al., 2004) and in humans (Booij et al., 2006; 386 
Nieuwenhuizen et al., 2009), as a consequence. The effect of the NaCNH and WPH 1 kDa 387 
permeates on cumulative food intake in male mice (C57Bl/6) was studied. No effect on food 388 
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intake was seen after administration of 200 mg kg
-1 
body weight (Fig. 6A and 6B). 389 
Nevertheless, following 500 mg kg
-1 
body weight administration of the NaCNH-1 kDa 390 
permeate, a significant reduction of cumulative food intake was observed (Fig. 6C and 6D). 391 
Repeated measures ANOVA showed a significant main effect of the treatment NaCNH-1 392 
kDa permeate vs. vehicle (F(1,18)=8.552; p < 0.01) and  a significant main effect of time 393 
(F(4.447,80.049)=834.962; p < 0.001). However, no significant interaction of time × 394 
treatment (F(4.447,80.049)=1.429; p = 0.228) was seen. Unhydrolyzed WP and NaCN did 395 
not demonstrate an effect on food intake, as no significant main effect of WP or NaCN 396 
compared to vehicle was observed, confirming the specificity of the anorexigenic effect of 397 
NaCNH-1 kDa permeate (Fig. 6G and 6H). Surprisingly, no significant effect on food intake 398 
was observed following IP administration of the WPH-1 kDa permeate when tested at 500 399 
mg kg
-1 
body weight (Fig. 6E and 6F). 400 
The lack of bioactivity seen with WPH-1 kDa permeate may be explained by the fact that the 401 
bioactive peptides within this sample were not bioavailable possibly due to their degradation 402 
by peptidases in the circulation or to a poor uptake in the target tissues. Future studies are 403 
needed to assess the orexigenic effect of these dairy-derived peptides following oral ingestion 404 
as well as the resulting plasma concentrations and kinetics of these orally administered 405 
bioactives. Bioactive peptides within the milk protein hydrolysates investigated in this study 406 
need to be able to cross the gut barrier and resist degradation by epithelial and serum 407 
peptidases. Previously, it has been shown that only minor fractions of dietary peptides reach 408 
the blood circulation due to proteolytic instability and poor absorption. However, intestinal 409 
transport of intact peptides has been reported in vivo (Gardner, 1983). The bioavailability of 410 
peptides is thought to be governed by their stability to gastrointestinal digestion, their 411 
permeability through the intestinal mucosa and stability to brush border and serum 412 
peptidases. 413 
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Casein-derived bioactive peptides could be detected in the jejunum of human subjects 414 
intubated with a nasogastric tube (Boutrou et al., 2013). Transepithelial transport of 415 
oligopeptides through a Caco-2 cell layer has been reported to be mainly governed by the 416 
hydrolytic activity of brush border peptidases (Shimizu, Tsunogai, & Arai, 1997). 417 
Degradation of the angiotensin converting enzyme (ACE) inhibitory peptide, Leu-His-Leu-418 
Pro-Leu-Pro, by brush border peptidases of Caco-2 cells has been reported to occur as early 419 
as 5 min (Quirós, Dávalos, Lasunción, Ramos, & Recio, 2008). However, the peptide 420 
released (His-Leu-Pro-Leu-Pro) by brush border peptidases was still bioactive and could 421 
cross the Caco-2 cell layer. Degradation of Val-Pro-Pro has also been shown, but intact 422 
material could be found in the basolateral compartment, showing that a certain proportion of 423 
Val-Pro-Pro could cross the Caco-2 cell monolayer without being degraded (Satake et al., 424 
2002). 425 
A few studies have demonstrated that specific peptide sequences could reach the circulation 426 
without being degraded. Following ingestion of a lacto-tripeptide enriched yogurt beverage, 427 
the ACE inhibitory peptide, Ile-Pro-Pro was found in its intact format in the blood circulation 428 
(Foltz et al., 2007). Other relatively hydrophobic dipeptides (Leu-Trp, Phe-Tyr and Ile-Tyr) 429 
were identified in the plasma following ingestion of the lacto-tripeptide enriched yoghurt 430 
beverage (Foltz et al., 2007). Moreover, the bioactive peptides found within hydrolysed 431 
NaCN are relatively small and hydrophobic in nature, which may suggest they have the 432 
potential to survive gastrointestinal digestion and allow for intestinal permeation (Morifuji et 433 
al., 2010; Nongonierma et al., 2013; Shimizu et al., 1997). Larger peptides may also cross the 434 
intestinal barrier and it has been reported that of peptides ≥ 5 amino acid length could 435 
permeate through a layer of Caco-2 cells (Quirós et al., 2008; Vermeirssen et al., 2002). 436 
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4. Conclusion 437 
In this study the 5-HT2C receptor activating potential of enzymatic hydrolysates of WP  and 438 
NaCN was demonstrated in vitro. It was shown that the serotonergic activation observed with 439 
the WHP-1 kDa permeate and the NaCNH-1 kDa permeate was specific for the 5-HT2C 440 
receptor, with no activation seen for the 5-HT2A and 5-HT2B receptors. This suggests that the 441 
bioactive peptides may induce less side effects generally associated with non-specific 442 
activation of the 5-HT2B receptor, which may lead to valvulopathy. The in vitro 5-HT2C 443 
activating potential of NaCNH-1 kDa permeate translated to a reduced cumulative food 444 
intake in mice. However, these effects were only observed at a high dose of sample following 445 
IP administration. In addition, no in vivo effect was seen upon administration of the WHP-1 446 
kDa permeate, despite the high potency on 5-HT2C receptor activation in vitro. The reason for 447 
the absence of an in vivo effect of the WPH derived hydrolysate permeate could be 448 
multifaceted and may be related to peptide stability, bioavailability or mal-absorption, and 449 
should be investigated further. The results described herein demonstrate the potential of milk-450 
protein derived bioactive peptides with 5-HT2C receptor agonist properties as satiating 451 
ingredients. These may be further exploited in the development of functional foods with anti-452 
obesity properties. 453 
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Table 1. Increased whey protein hydrolysate (WPH)-mediated intracellular calcium (Ca
2+
) in 726 
Hek-5-HT2C-INI cells upon enrichment of low molecular mass peptides in the ultrafiltration 727 
(UF) samples.  728 
Sample
1 
Relative increase in 
intracellular Ca
2+
 (% RFU)
2
 
WP -11.8 ± 0.9 
WPH 40.7 ± 2.2
a
 
WPH-10 kDa Ret -0.5 ± 2.6
b
 
WPH-10 kDa Perm 67.9 ± 2.7
 a,b
 
WPH-5 kDa Ret 42.8 ± 3.2
 a,b
 
WPH-5 kDa Perm 86.7 ± 3.5
 a,b
 
WPH-1 kDa Ret 76.7 ± 1.3
 a,b 
 
WPH-1 kDa Perm 97.1 ± 1.8
 a,b 
 
 
 729 
1
 WP: whey protein, WPH: 240 min whey protein hydrolysate, Perm: ultrafiltration (UF) 730 
permeate, Ret: UF retentate. 731 
2
 Relative increased in intracellular Ca
2+
 expressed as percentage of relative fluorescence 732 
units (RFU) with respect to serotonin (5-hydroxytryptamine, 5-HT)  (10 nM). Samples were 733 
tested at 0.5 mg mL
-1
. Average values ± SEM of three replicates. Statistical different values 734 
compared to WP (a; p<0.001) and compared to WPH (b; p<0.001) are indicated.  735 
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Figure captions 736 
 737 
Fig. 1 Schematic representation of the experimental design including the enzymatic 738 
hydrolysis, ultrafiltration fractionation and bioassay testing of the 1 kDa permeates of the  739 
240 min sodium caseinate (NaCNH-1 kDa permeate) and whey protein hydrolysates (WPH-1 740 
kDa permeate). 741 
 742 
Fig. 2 Whey protein hydrolysate (WPH)-mediated intracellular calcium (Ca
2+
) in human 743 
embryonic kidney (Hek) wild type (wt) () cells, Hek-5-HT2C-INI () and Hek-5-HT2C-744 
VSV () cells. Intracellular Ca2+ increase was depicted as a percentage of maximal Ca2+ 745 
increase as elicited by the control (3.3 % FBS). Graph represents the mean ± SEM of samples 746 
analysed in triplicate. Statistical different values are indicated for Ca
2+
 increases in Hek-5-747 
HT2C-INI cells compared to WP in Hek wt (a, p<0.001); for Hek-5-HT2C-VSV compared to 748 
WP in Hek wt (b, p<0.01); for Hek-5-HT2C-INI compared to WP in Hek-5-HT2C-INI (c, 749 
p<0.01 and d, p<0.001) and for Hek-5-HT2C-VSV compared to WP in Hek-5-HT2C-VSV (e, 750 
p<0.001) (A). Both the WPH-1 kDa permeate () and the NaCNH-1 kDa permeate () 751 
induce Ca
2+
 mobilization in cells expressing the 5-HT2C receptor as analysed in a 752 
concentration response curve. Intracellular Ca
2+
 increase was depicted as a percentage of 753 
maximal Ca
2+
 increase as elicited by the endogenous ligand, 5-HT (1uM). Graph represents 754 
the mean ± SEM of samples analysed in duplicate (B). 755 
 756 
Fig. 3 Reverse-phase ultraperformance liquid chromatographic (RP-UPLC) profile of (A) the 757 
unhydrolysed whey protein (WP), (B) 240 min whey protein hydrolysate (WPH), (C) 10 kDa 758 
retentate of WPH, (D) 10 kDa permeate of WPH (E) 5 kDa permeate of WPH and (F) the 1 759 
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kDa permeate of WPH. 1: caseinomacropeptide; 2: α-lactalbumin; 3: β-lactoglobulin. The 760 
analysis was conducted three times for the 240 min hydrolysate (n = 3), showing identical 761 
peptide profiles in the 3 instances. 762 
 763 
Fig. 4 Molecular mass distribution of the 240 min whey protein hydrolysate (WPH) and its 764 
associated ultrafiltration (UF) fractions. Molecular mass distribution:  : > 5 kDa; : 5-1 765 
kDa,  :  < 1 kDa. 766 
 767 
Fig. 5 Specificity of the NaCNH-1 kDa permeate and WPH-1 kDa permeate samples 768 
compared to 5-HT2 receptor activation mediated by the endogenous ligand, 5-HT (1uM). 769 
Intracellular calcium (Ca
2+
) increase was depicted as a percentage of maximal Ca
2+ 
increase 770 
as elicited by control (1 µM 5HT) in Hek-5-HT2A () cells, Hek-5-HT2B () and Hek-5-771 
HT2C () cells. Graph represents the mean ± SEM of samples analysed in duplicate. 772 
Statistical different values of 5-HT2C compared to 5-HT2A (a; p<0.001 and c; p<0.01) and 773 
compared to 5-HT2B (b; p<0.001) are indicated. 774 
 775 
Fig. 6 Cumulative food intake following administration of milk protein-derived hydrolysates. 776 
Food (regular chow) intake in C57Bl/6 male mice was determined following intraperitoneal 777 
(IP) injection with 200 mg kg
-1
 body weight (A, B) or 500 mg kg
-1
 body weight (C, D) 1 kDa 778 
permeate of the 240 min sodium caseinate hydrolysate (NaCNH-1 kDa permeate). The 1 kDa 779 
permeate of the 240 min whey protein hydrolysate (WPH-1 kDa permeate) was IP injected at 780 
500 mg kg
-1
 body weight (E, F). Unhydrolyzed WP and NaCN were also IP injected at 500 781 
mg kg
-1
 body weight (G, H). Cumulative food intake was determined at regular intervals after 782 
IP injection (A, C, E and G). Food intake per time bin was calculated (B, D, F and H). 783 
Statistical significance was determined using repeated measures ANOVA and estimation of 784 
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parameters; statistical significance depicted is notated as ** p < 0.01 and * p < 0.05; n = 10 785 
mice per treatment group.   786 
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 793 
 794 
 795 
 796 
 797 
 798 
 799 
 800 
NaCN: sodium caseinate; NaCNH: 240 min sodium caseinate hydrolysate; WP: whey 801 
proteins; WPH: 240 min whey protein hydrolysate; RP-UPLC: reverse phase 802 
ultraperformance liquid chromatography; GP-HPLC gel permeation-high performance liquid 803 
chromatography; Hek: human embryonic cells; 5HT2C: serotonin (5-hydroxytryptamine, 5-804 
HT) 2C receptor. 805 
 806 
 807 
Fig. 1  808 
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